18 / 40
ITT population (n=564)
130 rucaparib 66 placebo
+
106 rucaparib 52 placebo
+
139 rucaparib 71 placebo
HRD cohort (n=354)
130 rucaparib 66 placebo
+
106 rucaparib 52 placebo
BRCA
-mutant cohort (n=196)
130 rucaparib 66 placebo
564 enrolled/randomised
196
BRCA
mutant
368
BRCA
wild type
158
BRCA
wild type/
LOH high
‡
161
BRCA
wild type/
LOH low
49
BRCA
wild type/
LOH indeterminate
130 germline
BRCA
mutant*
56 somatic
BRCA
mutant
†
10 germline/somatic
unknown
Maintenance with
Rucaparib in BRCAwt
ARIEL 3: Cohorts by biomarker
LOH test, Foundation Medicine
Cut-off: 16%
Coleman R
et al
.
Lancet
2017